The rate of weight loss from onset to diagnosis can be a significant indicator of poorer outcomes among amyotrophic lateral sclerosis (ALS) patients, a study reports. The study, “Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort,” was published in the…

In addition to symptoms of depression, disease progression is one of the strongest influences on health-related quality of life in amyotrophic lateral sclerosis (ALS) patients, a study reports. According to the study, titled Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis,” slower disease progression is linked to…

CuATSM, one of the lead investigational therapies of Collaborative Medicinal Development (CMD), may slow disease progression and improve the respiratory and cognitive function of patients with amyotrophic lateral sclerosis (ALS), a Phase 1 trial shows. The findings of the multicenter, open-label, dose-finding study (NCT02870634) were announced by…

CloudMedx plans to develop a computer analysis algorithm that will track the clinical progression of patients with amyotrophic lateral sclerosis (ALS) to predict treatment outcomes. This tool will be the result of a new collaboration between the healthcare artificial intelligence (AI) company and the Gregory W. Fulton…

Researchers have developed a new small molecule that targets the most common genetic defect behind amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, a study reports. These findings suggest that therapies directed at the underlying cause of ALS and frontotemporal dementia may be achievable in the near future. The…

Sativex, a mixture of two active compounds of cannabis, may help control symptoms of spasticity (stiff muscles) in people with amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis, a Phase 2 trial shows. The study “Safety and efficacy of nabiximols on spasticity symptoms in patients with motor…

The majority of patients with amyotrophic lateral sclerosis (ALS) report wanting new treatments to stop their disease’s progression and so improve breathing function, muscle strength, and mobility, according to the results from a self-reported online survey of ALS patients and caregivers. These findings may help define future guidelines for the development…

Treatment with the anticonvulsant Potiga (ezogabine) lessened abnormal motor neuron excitability, or responsiveness, in patients with amyotrophic lateral sclerosis (ALS), according to top-line results of a Phase 2 clinical trial. Findings were presented at the recent 29th International Symposium on ALS/ Motor Neurone Disease in Glasgow, Scotland, by Brian…

Amyotrophic lateral sclerosis (ALS) patients with impaired swallowing show loss of taste perception, according to a new study. This problem is greater in patients requiring a feeding tube. The findings also suggested that using a device reproducing original food flavor may improve the patients’ quality of life. The study,…

A new research project that will investigate the seemingly unrelated mechanisms between neurodegenerative diseases and infections has been awarded $2.5 million from the Chan Zuckerberg Initiative (CZI). The funding was awarded to Ivan Marazzi, PhD, assistant professor of microbiology at the Icahn School of Medicine at Mount Sinai in New…